Anti-PD-1 Monoclonal Antibody QL1604 clinical trials
Also written QL1604.
How each study uses Anti-PD-1 Monoclonal Antibody QL1604 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- QL1604
- 5
Studies by the year they started
6 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Anti-PD-1 Monoclonal Antibody QL1604 is the comparator. A study of two new drugs counts under both.
- 1Iparomlimab/Tuvonralimab · Qilu Pharmaceutical Co., Ltd. · next primary completion Mar 2028
Studies
Open first, then newest update. How each study uses Anti-PD-1 Monoclonal Antibody QL1604 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical CancerTerminatedPhase 2/3Qilu Pharmaceutical Co., Ltd.NCT04864782Written as QL1604
- A Phase I Study of QL1604 for Advanced Solid TumorsStatus unknownPhase 1Qilu Pharmaceutical Co., Ltd.NCT05801094Written as QL1604
- A Phase I Study of QL1604 in Subjects With Advanced Solid TumorsStatus unknownPhase 1Qilu Pharmaceutical Co., Ltd.NCT05649761Written as QL1604 injection
- QL1604 Monotherapy for dMMR or MSI-H Advanced Solid TumorsStatus unknownPhase 2Qilu Pharmaceutical Co., Ltd.NCT04326829Written as QL1604
- A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular CarcinomaStatus unknownPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT05603039Written as QL1604
- A Study of QL1604 Plus Nab-paclitaxel Versus Paclitaxel in Subjects With Advanced Gastric Cancer.Status unknownPhase 2/3Qilu Pharmaceutical Co., Ltd.NCT04435652Written as QL1604